Jazz’s Midphase Tremor Drug Misses Mark, Future Uncertain by Lilu Anderson 20.06.2024 Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Esperion Stock Downgraded Amid Merck’s Competitive Pressure by Mark Eisenberg 20.06.2024 Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
ADC Therapeutics Director Azelby Sells Shares Amid Price Target Cut by Mark Eisenberg 20.06.2024 Robert Azelby sells $20,215 in ADC Therapeutics shares for tax reasons; holds 53,005 shares. Investors eye insider actions for future ...
Iontronic Tech Promises Hope in Slowing Malignant Brain Tumors by Lilu Anderson 20.06.2024 "Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
Day One Biopharma Expands to ADCs with $55M Drug Acquisition by Lilu Anderson 19.06.2024 "Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
7 Breakthrough Biotech Stocks to Boost Your Portfolio in 2023 by Lilu Anderson 18.06.2024 "Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Aerovate Therapeutics Stock Downgraded After Trial Setback by Mark Eisenberg 17.06.2024 Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
Roche’s Hemlibra Battles Fierce Competition Amid Rating Hold by Mark Eisenberg 17.06.2024 Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...
Crypto Deposits to Chinese Drug Producers Double in 2024 by John Darbie 16.06.2024 Bitcoin dominates with 60% of crypto transaction volume. TRON and Ethereum follow. 70% of drug precursor sales linked to 11 ...
Avidity Biosciences CFO Sells $3.7M in Stock Amid Positive News by Terry Bingman 15.06.2024 Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.